Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy
نویسندگان
چکیده
منابع مشابه
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy
Paclitaxel is an anticancer agent effective for the treatment of breast, ovarian, lung, and head and neck cancer. Because of water insolubility, paclitaxel is formulated with the micelle-forming vehicle Cremophor EL to enhance drug solubility. However, the addition of Cremophor EL results in hypersensitivity reactions, neurotoxicity, and altered pharmacokinetics of paclitaxel. To circumvent the...
متن کاملa paradigm shift away from method-wise teaching to strategy-wise teaching: an investigation of reconstructive strategy versus communicative strategy
چکیده: هدف اصلی این مطالعه ی توصیفی تحقیقی در حقیقت تلاشی پساروش-گرا به منظور رسیدن به نتیجه ای منطقی در انتخاب مناسبترین راهکار آموزشی بر گرفته از چارچوب راهبردی مطرح شده توسط والدمر مارتن بوده که به بهترین شکل سازگار و مناسب با سامانه ی آموزشی ایران باشد. از این رو، دو راهکار آموزشی، راهکار ارتباطی و راهکار بازساختی، برای تحقیق و بررسی انتخاب شدند. صریحاً اینکه، در راستای هدف اصلی این پژوهش، ر...
15 صفحه اولInfluence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
PURPOSE Low-dose metronomic chemotherapy treatments, especially when combined with 'dedicated' antiangiogenic agents, can induce significant antitumor activity without serious toxicity in various preclinical models. It remains unclear, however, whether some cytotoxic drugs are better suited for metronomic regimens than others. Paclitaxel appears to be a strong candidate for metronomic chemother...
متن کاملInvestigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy.
Paclitaxel and carboplatin chemotherapy is reported to be a platelet-sparing drug combination. This study investigated potential mechanisms for this observation by studying the effects of paclitaxel and carboplatin on (1) normal donor and chemotherapy patient-derived erythroid (burst-forming units-erythroid [BFU-E]), myeloid (colony-forming units-granulocyte/macrophage [CFU-GM]), and megakaryoc...
متن کاملPaclitaxel-based combination chemotherapy for breast cancer.
Clinical trials to develop paclitaxel (Taxol)-containing combinations started in 1992 with several approaches to combine doxorubicin and paclitaxel. Schedule-dependent toxicity limited doses in the initial trials, although antitumor activity was high. More recently, a well-tolerated, highly effective doxorubicin/paclitaxel regimen was developed with the use of bolus anthracycline administration...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutics and Clinical Risk Management
سال: 2005
ISSN: 1176-6336
DOI: 10.2147/tcrm.1.2.107.62910